Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 24, 2021 08:00 ET | Source: Excision BioTherapeutics

Excision BioTherapeutics Appoints Biotechnology Development and Manufacturing Veteran, Franz Gerner, Ph.D., as Chief Technology Officer & Head of Manufacturing

SAN FRANCISCO, May 24, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...
May 05, 2021 08:00 ET | Source: Excision BioTherapeutics

Excision BioTherapeutics Adds Gene Therapy Expert Nicole Paulk, Ph.D., to its Scientific Advisory Board

SAN FRANCISCO, May 05, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...
May 03, 2021 08:00 ET | Source: Excision BioTherapeutics

Excision BioTherapeutics Appoints Seasoned Finance Executive Christine Silverstein as Chief Financial Officer

SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...
April 01, 2021 08:00 ET | Source: Excision BioTherapeutics

Excision BioTherapeutics Appoints Biotechnology Industry Research & Development Veteran, William Kennedy, M.D., as Senior Vice President, Clinical Development

SAN FRANCISCO, April 01, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...
February 17, 2021 08:00 ET | Source: Excision BioTherapeutics

Excision BioTherapeutics Completes $60 Million Financing to Advance CRISPR-Based Infectious Disease Programs

SAN FRANCISCO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...
November 30, 2020 14:47 ET | Source: Excision BioTherapeutics

HIV-Like Virus Eliminated from the Genomes of Primates; Excision BioTherapeutics Advancing the Innovation to Clinical Development

San Francisco, CA, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Taking a major step forward in HIV research, scientists at the Lewis Katz School of Medicine at Temple University have successfully edited SIV –...
November 03, 2020 09:00 ET | Source: Excision BioTherapeutics

CRISPR-Focused Excision BioTherapeutics Announces Business Advisory Board and Addition of Interim Chief Business Officer

SAN FRANCISCO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapeutics to cure viral infectious diseases, announced today the...
August 04, 2020 12:00 ET | Source: Excision BioTherapeutics

Excision BioTherapeutics Appoints Veteran Genome Editing Expert TJ Cradick, PhD as Chief Scientific Officer

San Francisco, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, a biotechnology company dedicated to curing viral infectious disease using CRISPR, today announced the appointment of TJ...
March 11, 2020 15:27 ET | Source: Excision BioTherapeutics

Excision BioTherapeutics Announces Data Presentation at CROI from IND-Enabling Non-Human Primate studies of EBT-001, supporting a CRISPR Gene Editing Technology for HIV Elimination

OAKLAND, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, a private biotechnology company focused on applying CRISPR gene editing to curing viral infectious diseases, today...
December 03, 2019 12:30 ET | Source: Excision BioTherapeutics

CRISPR-focused Excision BioTherapeutics Strengthens Board of Directors Appointing Veteran Pharmaceutical Executive Bill Carson, M.D.

Oakland, CA, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced that...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right